These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 22271949)
21. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada. Poirier B; De Wals P; Petit G; Erickson LJ; Pépin J Vaccine; 2009 Nov; 27(50):7105-9. PubMed ID: 19786137 [TBL] [Abstract][Full Text] [Related]
22. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers. Chandrasekharan S; Amin T; Kim J; Furrer E; Matterson AC; Schwalbe N; Nguyen A Vaccine; 2015 Nov; 33(46):6366-70. PubMed ID: 26368398 [TBL] [Abstract][Full Text] [Related]
23. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Berndt ER; Glennerster R; Kremer MR; Lee J; Levine R; Weizsäcker G; Williams H Health Econ; 2007 May; 16(5):491-511. PubMed ID: 17013993 [TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany. Claes C; Graf von der Schulenburg JM Pharmacoeconomics; 2003; 21(8):587-600. PubMed ID: 12751916 [TBL] [Abstract][Full Text] [Related]
25. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M Value Health; 2004; 7(1):36-51. PubMed ID: 14720129 [TBL] [Abstract][Full Text] [Related]
26. Issues in pneumococcal disease and pneumococcal conjugate vaccines: highlights of the 27th meeting of ESPID, Brussels, Belgium, June 9-13, 2009. Adam D Vaccine; 2009 Nov; 27(50):7133-7. PubMed ID: 19883868 [TBL] [Abstract][Full Text] [Related]
27. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model. By A; Sobocki P; Forsgren A; Silfverdal SA Clin Ther; 2012 Jan; 34(1):177-89. PubMed ID: 22284997 [TBL] [Abstract][Full Text] [Related]
28. Pneumococcal Vaccines--a Real World Perspective. Swaminathan S; Balajee G J Assoc Physicians India; 2015 Apr; 63(4 Suppl):25-8. PubMed ID: 26562960 [No Abstract] [Full Text] [Related]
29. Pneumococcal conjugate vaccine introduction in Latin America and the Caribbean: progress and lessons learned. de Oliveira LH; Trumbo SP; Ruiz Matus C; Sanwogou NJ; Toscano CM Expert Rev Vaccines; 2016 Oct; 15(10):1295-304. PubMed ID: 26982434 [TBL] [Abstract][Full Text] [Related]
30. Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine ( Alderson MR; Sethna V; Newhouse LC; Lamola S; Dhere R Hum Vaccin Immunother; 2021 Aug; 17(8):2670-2677. PubMed ID: 33625961 [TBL] [Abstract][Full Text] [Related]
31. Evaluating the costs and benefits of pneumococcal vaccination in adults. Porchia BR; Bonanni P; Bechini A; Bonaccorsi G; Boccalini S Expert Rev Vaccines; 2017 Feb; 16(2):93-107. PubMed ID: 27680425 [TBL] [Abstract][Full Text] [Related]
32. Status of research and development of pediatric vaccines for Streptococcus pneumoniae. Alderson MR Vaccine; 2016 Jun; 34(26):2959-2961. PubMed ID: 27083428 [TBL] [Abstract][Full Text] [Related]
33. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults. Feldman C; Dlamini SK; Madhi SA; Meiring S; von Gottberg A; de Beer JC; de Necker M; Stander MP PLoS One; 2020; 15(1):e0227945. PubMed ID: 31995597 [TBL] [Abstract][Full Text] [Related]
34. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America. Giglio N; Micone P; Gentile A Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351 [TBL] [Abstract][Full Text] [Related]
35. Pneumococcal infection and vaccination in the elderly. Vlasich C Vaccine; 2001 Mar; 19(17-19):2233-7. PubMed ID: 11257339 [TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia. Lara C; De Graeve D; Franco F Value Health Reg Issues; 2018 Dec; 17():21-31. PubMed ID: 29626706 [TBL] [Abstract][Full Text] [Related]
38. Response to "Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries". Strutton D; Hwang S; Farkouh R; Roberts C Vaccine; 2011 Oct; 29(44):7589-90; author reply 7591-2. PubMed ID: 21406264 [TBL] [Abstract][Full Text] [Related]
39. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review. Saokaew S; Rayanakorn A; Wu DB; Chaiyakunapruk N Pharmacoeconomics; 2016 Dec; 34(12):1211-1225. PubMed ID: 27510721 [TBL] [Abstract][Full Text] [Related]
40. Pneumococcal whole-cell and protein-based vaccines: changing the paradigm. Pichichero ME Expert Rev Vaccines; 2017 Dec; 16(12):1181-1190. PubMed ID: 29130395 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]